Keryx Biopharmaceuticals, Inc. (KERX) Price Down, Not Company's Potential - International Business Times PDF Print
International Business Times
Regarding therapies for end-stage renal disease (ESRD), a more than billion-dollar market controlled by Genzyme (NASDAQ:GENZ) with Renagel and Renvela,

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.